Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077535 | 0.85 | LIPG (0.51) | HSD17B10LIPGCYP2C19LMNAKMT2A | |
| SCHEMBL6078915 | 0.81 | LIPG (0.48) | HSD17B10LIPGPOLBLMNAMEN1 | |
| SCHEMBL6078249 | 0.74 | PARP1 (0.45) | LIPGPOLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28214151 | 0.72 | HSD17B10 (0.66) | HSD17B10POLBCYP2C19LMNAKMT2A | |
| SCHEMBL6077393 | 0.72 | LIPG (0.39) | HSD17B10LIPGKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL6077541 | 0.71 | LIPG (0.48) | LIPG | |
| SCHEMBL24412634 | 0.71 | HSD17B10 (0.68) | HSD17B10CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL29070246 | 0.71 | HSD17B10 (0.68) | HSD17B10POLBCYP2C19LMNAMEN1 | |
| SCHEMBL6077906 | 0.71 | LIPG (0.38) | LIPGALDH1A1 | |
| SCHEMBL6078320 | 0.71 | LIPG (0.38) | LIPGPOLBLMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | HSD17B10 233/4885LIPG 2895/4885POLB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.